These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2898733)

  • 1. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.
    Goldman L; Sia ST; Cook EF; Rutherford JD; Weinstein MC
    N Engl J Med; 1988 Jul; 319(3):152-7. PubMed ID: 2898733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
    Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
    Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T; Berger K; Schulte-Hillen J; Kleber FX
    Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
    Newby LK; Eisenstein EL; Califf RM; Thompson TD; Nelson CL; Peterson ED; Armstrong PW; Van de Werf F; White HD; Topol EJ; Mark DB
    N Engl J Med; 2000 Mar; 342(11):749-55. PubMed ID: 10717009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.
    Almbrand B; Johannesson M; Sjöstrand B; Malmberg K; Rydén L
    Eur Heart J; 2000 May; 21(9):733-9. PubMed ID: 10739728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ].
    Golán L; Simek S; Linhart A; Cahlík T; Palecek T; Lubanda JC; Korínek J; Beran S; Aschermann M
    Vnitr Lek; 2003 Feb; 49(2):97-102. PubMed ID: 12728575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
    Le Pen C; Lévy E; Bonte J
    Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
    Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
    Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
    Wienbergen H; Zeymer U; Gitt AK; Juenger C; Schiele R; Heer T; Towae F; Senges J;
    Am J Cardiol; 2007 May; 99(9):1208-11. PubMed ID: 17478143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellners Y
    Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction.
    van Domburg RT; Sonnenschein K; Nieuwlaat R; Kamp O; Storm CJ; Bax JJ; Simoons ML
    J Am Coll Cardiol; 2005 Jul; 46(1):15-20. PubMed ID: 15992629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study.
    Wilhelmsen L; Welin L; Odén A; Björnberg A
    Eur J Health Econ; 2010 Apr; 11(2):177-84. PubMed ID: 19495819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.